Baidu
map

Alzheimer''s & Dementia:系统评价荟萃分析全球痴呆患病率

2013-04-10 刘沛 编译 医学论坛网

痴呆的流行病学证据资料正迅速地扩展起来,特别是在低收入或中等收入水平的国家。因其对社会政策和发展计划的影响十分重要,需要对全球的发病率和患者数进行再评估。近日,发表在2013年1月《阿尔茨海默病与痴呆症:阿尔茨海默病学会杂志》上的一篇研究对全球痴呆患病率进行了荟萃分析。  研究对全球范围内关于痴呆患病率的文献(1980-2009)进行了系统性的回顾及荟萃分析,评估患病率和发病人数、≥60岁的病人数

痴呆的流行病学证据资料正迅速地扩展起来,特别是在低收入或中等收入水平的国家。因其对社会政策和发展计划的影响十分重要,需要对全球的发病率和患者数进行再评估。近日,发表在2013年1月《阿尔茨海默病与痴呆症:阿尔茨海默病学会杂志》上的一篇研究对全球痴呆患病率进行了荟萃分析。
  研究对全球范围内关于痴呆患病率的文献(1980-2009)进行了系统性的回顾及荟萃分析,评估患病率和发病人数、≥60岁的病人数以及21个疾病负担区域的病人数。
  结果显示,60岁及以上的人群中,年龄标准化的患病率在全球范围内为5%-7%,拉丁美洲的患病率较高(8.5%),在撒哈拉以南非洲区域的患病率很低(2%-4%)。据估计,2010年全世界共有3560万痴呆患者,每20年发病人数可能会翻一番。在2030年痴呆患者可能达到6570万,2050年将达11540万。2010年,58%的痴呆患者生活在低收入或中等收入国家,到2030年这一比例将达到63%,2050年将达到71%。
  本研究详细的评估为政策制定和痴呆治疗及护理等福利保障提供了证据。痴呆的年龄特异性发病率在世界各地差异不大,并可能进一步缩小。今后对痴呆患者的护理应着眼于预防性干预(降低发病率)、提高治疗和护理水平(延长生存期)以及根据疾病调整干预措施(避免或延缓进展)。所有国家都应进行全国范围的调查并定期监测趋势。

痴呆相关的拓展阅读:


The global prevalence of dementia: A systematic review and metaanalysis
Background
The evidence base on the prevalence of dementia is expanding rapidly, particularly in countries with low and middle incomes. A reappraisal of global prevalence and numbers is due, given the significant implications for social and public policy and planning.
Methods
In this study we provide a systematic review of the global literature on the prevalence of dementia (1980–2009) and metaanalysis to estimate the prevalence and numbers of those affected, aged ≥60 years in 21 Global Burden of Disease regions.
Results
Age-standardized prevalence for those aged ≥60 years varied in a narrow band, 5%–7% in most world regions, with a higher prevalence in Latin America (8.5%), and a distinctively lower prevalence in the four sub-Saharan African regions (2%–4%). It was estimated that 35.6 million people lived with dementia worldwide in 2010, with numbers expected to almost double every 20 years, to 65.7 million in 2030 and 115.4 million in 2050. In 2010, 58% of all people with dementia lived in countries with low or middle incomes, with this proportion anticipated to rise to 63% in 2030 and 71% in 2050.
Conclusion
The detailed estimates in this study constitute the best current basis for policymaking, planning, and allocation of health and welfare resources in dementia care. The age-specific prevalence of dementia varies little between world regions, and may converge further. Future projections of numbers of people with dementia may be modified substantially by preventive interventions (lowering incidence), improvements in treatment and care (prolonging survival), and disease-modifying interventions (preventing or slowing progression). All countries need to commission nationally representative surveys that are repeated regularly to monitor trends.
    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1681246, encodeId=bcc0168124601, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Mar 02 08:04:00 CST 2014, time=2014-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717959, encodeId=682c1e17959a0, content=<a href='/topic/show?id=8f0658433a' target=_blank style='color:#2F92EE;'>#dementia#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5843, encryptionId=8f0658433a, topicName=dementia)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=307e32501717, createdName=linlin2323, createdTime=Thu Apr 11 22:04:00 CST 2013, time=2013-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836838, encodeId=b3ef183683835, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Fri Nov 29 18:04:00 CST 2013, time=2013-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250381, encodeId=686412503813f, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Fri Apr 12 00:04:00 CST 2013, time=2013-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444058, encodeId=38841444058ad, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Fri Apr 12 00:04:00 CST 2013, time=2013-04-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1681246, encodeId=bcc0168124601, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Mar 02 08:04:00 CST 2014, time=2014-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717959, encodeId=682c1e17959a0, content=<a href='/topic/show?id=8f0658433a' target=_blank style='color:#2F92EE;'>#dementia#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5843, encryptionId=8f0658433a, topicName=dementia)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=307e32501717, createdName=linlin2323, createdTime=Thu Apr 11 22:04:00 CST 2013, time=2013-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836838, encodeId=b3ef183683835, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Fri Nov 29 18:04:00 CST 2013, time=2013-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250381, encodeId=686412503813f, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Fri Apr 12 00:04:00 CST 2013, time=2013-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444058, encodeId=38841444058ad, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Fri Apr 12 00:04:00 CST 2013, time=2013-04-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1681246, encodeId=bcc0168124601, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Mar 02 08:04:00 CST 2014, time=2014-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717959, encodeId=682c1e17959a0, content=<a href='/topic/show?id=8f0658433a' target=_blank style='color:#2F92EE;'>#dementia#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5843, encryptionId=8f0658433a, topicName=dementia)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=307e32501717, createdName=linlin2323, createdTime=Thu Apr 11 22:04:00 CST 2013, time=2013-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836838, encodeId=b3ef183683835, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Fri Nov 29 18:04:00 CST 2013, time=2013-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250381, encodeId=686412503813f, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Fri Apr 12 00:04:00 CST 2013, time=2013-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444058, encodeId=38841444058ad, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Fri Apr 12 00:04:00 CST 2013, time=2013-04-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1681246, encodeId=bcc0168124601, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Mar 02 08:04:00 CST 2014, time=2014-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717959, encodeId=682c1e17959a0, content=<a href='/topic/show?id=8f0658433a' target=_blank style='color:#2F92EE;'>#dementia#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5843, encryptionId=8f0658433a, topicName=dementia)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=307e32501717, createdName=linlin2323, createdTime=Thu Apr 11 22:04:00 CST 2013, time=2013-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836838, encodeId=b3ef183683835, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Fri Nov 29 18:04:00 CST 2013, time=2013-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250381, encodeId=686412503813f, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Fri Apr 12 00:04:00 CST 2013, time=2013-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444058, encodeId=38841444058ad, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Fri Apr 12 00:04:00 CST 2013, time=2013-04-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1681246, encodeId=bcc0168124601, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Sun Mar 02 08:04:00 CST 2014, time=2014-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717959, encodeId=682c1e17959a0, content=<a href='/topic/show?id=8f0658433a' target=_blank style='color:#2F92EE;'>#dementia#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5843, encryptionId=8f0658433a, topicName=dementia)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=307e32501717, createdName=linlin2323, createdTime=Thu Apr 11 22:04:00 CST 2013, time=2013-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836838, encodeId=b3ef183683835, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Fri Nov 29 18:04:00 CST 2013, time=2013-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250381, encodeId=686412503813f, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Fri Apr 12 00:04:00 CST 2013, time=2013-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444058, encodeId=38841444058ad, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Fri Apr 12 00:04:00 CST 2013, time=2013-04-12, status=1, ipAttribution=)]
    2013-04-12 huagfeg

相关资讯

ACS Chem Neurosci:揭示橄榄油预防阿尔茨海默病机制

食用特级初榨橄榄油(extra virgin olive oil)如何精确地有助于降低患上阿尔茨海默病(Alzheimer's disease, AD)的风险是一个谜。在一项新的研究中,研究人员报道解决这个谜的关键可能在于橄榄油中的一种组分,这个组分有助于将异常的AD蛋白从大脑中运输出去。相关研究结果于2013年2月15日在线发表在ACS Chemical Neuroscience期刊上,论文标题

JAMA:痴呆症非药物治疗六步走

  基于现有证据和自身临床经验,约翰·霍普金斯大学的Laura N. Gitlin博士等研究者提出了痴呆症非药物治疗六步法,以便更好地识别和处理痴呆症患者的行为问题。这篇文章发表在11月21日《美国医学会杂志》上(JAMA. 2012;308(19):2020-2029)。   行为问题可包括诸如抑郁、精神错乱、冷漠、狂躁、攻击性、错觉和幻觉等精神症状,也包括诸如反复发声和闲逛等异常行

BIB:阿尔茨海默病评估量表可能不完善(ADNI研究)

  研究者从ADNI(阿尔辞海默病神经影像创新)研究中选取了193例受试者的资料,以评价ADAS-Cog(阿尔茨海默病评估量表-认知行为部分)评分是否仍有需要改进之处。受试者的平均年龄为74岁,47%为女性,平均Mini精神状态检查评分为23分。资料包括基线、6个月、12个月和24个月时675项指标的评分。   结果未发现可能限制量表识别低功能或高功能患者状态变化的总体效能的地板效应和天花板效应

JCI:宋伟宏等发现抑制阿尔茨海默病发生新靶点

重庆医科大学附属儿童医院宋伟宏教授和加拿大不列颠哥伦比亚大学的合作研究团队找到了一种全新的可干预阿尔茨海默病发病的靶点。该研究报告日前在国际《临床研究杂志》J Clin Invest.上发表。 阿尔茨海默病,俗称老年痴呆症,发病原因不清,也没有有效的预防和治疗的方法。目前认为一种叫Aβ的毒性淀粉样蛋白在大脑里形成的老年神经斑,是导致阿尔茨海默病的重要原因。宋伟宏团队的研究发现,糖原合成酶激酶3β

Neurology:罹患AD,出血性卒中风险增加

  罹患卒中可增加痴呆[包括阿尔茨海默病(AD)]风险,但反之是否亦然尚不可知。一项芬兰和瑞典联合研究显示,罹患AD的患者,尤其是年轻患者,发生出血性卒中风险增加。论文发表于《神经病学》[Neurology 2013,80(4):353]杂志。   研究纳入确诊AD的社区患者50808例(平均79.6岁,除外有卒中史者)及未患AD匹配对照。在2006年1月1日至2009年12月31日间

Molecules:草花总黄酮或可用于治疗阿尔茨海默病

草花总黄酮对细胞存活的保护作用 阿尔茨海默病(Alzheimer’S disease,AD)是一种多发于中老年期的中枢神经系统退行性疾病,也是我们常说的老年痴呆症,患者典型的临床症状为进行性的记忆障碍和认知功能不断恶化,日常生活能力进行性减退,并具有各种神经症状和行为障碍。伴随社会老龄化的进程,AD的发病率逐年上升,已经成为严重的社会问题。 中科院新疆理化技术研究所资源化学研究室科研人员从

Baidu
map
Baidu
map
Baidu
map